

# MARAPHARM

CSE:MDM

FSE:2M0

OTCQB:MRPHF

Kelowna, British Columbia

[info@marapharm.com](mailto:info@marapharm.com)

Telephone: **778-583-4476**

---

## News Release

March 30, 2017

### **Marapharm Ventures Inc., Kelowna BC, "Marapharm" announces \$3,570,000 of warrants exercised for first quarter of 2017**

Marapharm is pleased to announce that \$3,570,000.00 has been received from the exercise of warrants in the first quarter of 2017.

Linda Sampson, Marapharm CEO notes, "We are very pleased that our shareholders have the confidence in Marapharm by increasing their ownership positions, through the exercising of their warrants. We will use this \$3,570,000 million for further development and working capital. We will continue to search for acquisition opportunities, particularly in California."

#### **ABOUT MARAPHARM VENTURES INC.**

[www.marapharm.com](http://www.marapharm.com)

Construction photos and videos are on the web site. Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.

Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV and about two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (Production and Sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.

Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through

the CSE website ([www.thecse.com](http://www.thecse.com)), the OTC website ([www.otcmarkets.com](http://www.otcmarkets.com)) and Sedar website ([www.sedar.com](http://www.sedar.com)) under the profile for Marapharm Ventures Inc.

FOR FURTHER INFORMATION:

[www.marapharm.com](http://www.marapharm.com) or Linda Sampson, CEO, 778-583-4476 [info@marapharm.com](mailto:info@marapharm.com)

STOCK EXCHANGES:

*Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.*

FORWARD - LOOKING STATEMENTS:

Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.